In PWA mice, treatment with GLP1/E caused a significant decrease in body weight (10%) and fat mass (50%), as well as a reduction in food intake and substantial improvement in glucose metabolism and insulin sensitivity, denoted by ITT and HOMA-IR, as well as serum glucose, insulin (Fig
Ipamorelin is a selective pentapeptide growth hormone secretagogue (GHS) that stimulates pituitary GH release by mimicking ghrelin at the GHSR-1a receptor without the cortisol, prolactin, or ACTH elevation associated with earlier GHRPs, making it the cleanest GH secretagogue in the research literature and the most common partner peptide in CJC-1295/Ipamorelin combination stacks
Weve been following the therapeutic peptide space for years
Developments Semaglutide and Liraglutide Litigation On October 6, 2023, Siskinds filed a proposed class action in the Supreme Court of British Columbia on behalf a proposed class of Canadians who suffered injuries arising from the consumption of GLP-1 drugs manufactured by Novo Nordisk, which was subsequently amended on October 3, 2025